Deborah K Armstrong
Affiliation: Johns Hopkins University
Krasner C, Castro C, Penson R, Roche M, Matulonis U, Morgan M, et al
. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019;153:223-229 pubmed publisher
..5-NR) and 79.7 (95%CI 59.0-79.7) months, respectively for Trial A and B. Weekly administered IP carboplatin and IP paclitaxel is tolerable and safe with similar activity with and without concommittant bevacizumab in these 2 trials. ..
Landrum L, Brady W, Armstrong D, Moore K, DiSilvestro P, O Malley D, et al
. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016;140:204-9 pubmed publisher
..o. b.i.d. in women with recurrent, platinum-sensitive ovarian cancer. With bevacizumab, DLTs were noted in 9 out of 12 patients. Lower doses of veliparib will need to be considered when given in combination with platinum-based therapies. ..
Oliver K, Brady W, Birrer M, Gershenson D, Fleming G, Copeland L, et al
. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017;147:243-249 pubmed publisher
..Finally, treatment effect was influenced by histology. ..
Moore K, Tritchler D, Kaufman K, Lankes H, Quinn M, Van Le L, et al
. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;147:396-401 pubmed publisher
..The SNP's identified in this GWAS study will require validation and these preliminary findings may lead to identification of novel pathways and biomarkers. ..